Method for detecting beta-sheet aggregate forms of proteins that form beta-sheet aggregates

Abstract

The present invention relates to an in vitro method for detecting the β-sheet aggregate form of a protein that forms β-sheet aggregates (PAFβ) in a sample, comprising the steps of adjusting the pH of a sample likely to contain PAFβ to a pH in the range of 9.7 to 13.2, and measuring the PNAFβ content using a suitable immunological method at a pH in the range of 6 to 9, in order to isolate all or a portion of the PAFβ to obtain the β-sheet non-aggregated form of a protein that forms β-sheet aggregates (PNAFβ).

Description

[Technical Field]

[0001] The present invention relates to an in vitro method for detecting the β-sheet aggregate form of a protein that forms β-sheet aggregates (PAFβ) in a sample, the method comprising the steps of disaggregating PAFβ to obtain the β-sheet non-aggregated form of a protein that forms β-sheet aggregates (PNAFβ) and measuring the PNAFβ content. [Background technology]

[0002] The accumulation of misfolded proteins often leads to their aggregation in cells, causing cellular dysregulation, particularly characteristic of certain neurodegenerative pathologies. Beta-amyloid peptides, more specifically the β1-42 amyloid peptide, have been extensively studied for the formation of β-sheet-containing fibrils and then plates in Alzheimer's disease. The aggregation process of β-amyloid peptides has been well characterized, and this process varies depending on several factors, particularly their concentration, pH, and temperature. Many other proteins containing prion-like domains, such as RNA- and DNA-binding proteins, can also form prion-like aggregates [1]. A protein containing a prion-like domain is the β-sheet aggregate-forming protein (PFβ).

[0003] The prion-like domain contains hydrophobic amino acids that promote the formation of β-sheet-rich fibrils. The β-sheet aggregate form of the protein (PAFβ) that forms β-sheet aggregates is not soluble in water at neutral pH.

[0004] Current diagnosis of these PAFβ-induced neurodegenerative diseases is mostly based on imaging, which is complemented by clinical and neuropsychological testing, a cumbersome and expensive procedure requiring several diagnostic steps.

[0005] Various diagnostic techniques that make it possible to demonstrate or quantify PFβ aggregation or oligomerization in biological samples are also described in the literature.

[0006] Structural analysis techniques have made it possible to highlight the various levels of aggregation of certain PFβ proteins, particularly the β-amyloid peptide and TAU or TDP-43 proteins: electron microscopy, atomic force microscopy, cryo-electron microscopy, circular dichroism, nuclear magnetic resonance, and X-ray diffraction. However, these techniques make it difficult to measure the aggregate content present in a sample, even relative amounts. Therefore, these techniques do not easily allow for the study of the potential effects of compounds on the level of PFβ aggregation (especially its inhibition).

[0007] Techniques that allow for the separation of proteins according to their molecular weight make it possible to distinguish between high- and low-molecular-weight PAFβ. Some of them also allow for the differentiation of aggregates of various sizes. For example, mention can be made of polyacrylamide gel electrophoresis (PAGE and SDS-PAGE), with or without Western blot detection. However, the experimental conditions currently described in these techniques can distort the measurement of the level of aggregation. This is especially true for SDS-PAGE, where the combined use of detergents and reducing agents (DTT, beta-mercaptoethanol, or TCEP) can dissociate all or part of the aggregates. Due to their experimental limitations (execution time, large sample amounts, lack of sensitivity), these techniques are not really suitable for characterizing compounds capable of modulating the level of PAFβ aggregation.

[0008] Immunodetection-based techniques have also been described: - Filtration combined with immunodetection: In this method, a biological sample is filtered through a membrane capable of retaining high molecular weight species, particularly PAFβ. Antibodies specific for PAFβ, directly or indirectly labeled with a chromogenic, fluorescent, or even luminescent tracer, are then applied to the membrane. The measured signal is directly proportional to the amount of PAFβ. This method may be adapted to a microplate format to study the effects of compounds on amyloid protein aggregation parameters or levels. However, the automation and throughput of the method are limited due to the filtration and washing steps required by this technique [2].

[0009] - ELISA: To characterize PFβ aggregation, various ELISA test strategies have been described. The first strategy involves using the same antibody that captures PAFβ on a solid phase as the tracer that allows its detection. This method allows for the detection of only PAFβ, which has several epitopes on the antibodies used for capture and detection. Conversely, the capture and detection antibodies cannot be simultaneously immobilized on PNAFβ, since they only have one epitope recognized by the antibody used. Therefore, no signal is generated in the presence of PNAFβ [3]. The second strategy involves combining an antibody that specifically recognizes PAFβ with an antibody that recognizes all forms of PFβ (PAFβ and PNAFβ) present in the sample in an ELISA test [4]. In this format, the PAFβ-specific antibody is generally the capture antibody, but formats using it as the detection antibody have also been described [5]. The third strategy involves using two different antibodies that both recognize the PAFβ of interest. This last strategy appears to improve the specificity of aggregate detection [6]. All these ELISA tests allow to determine the level of aggregation of the target PFβ and to determine the effect of compounds on that level of aggregation. Nevertheless, the detection of PAFβ alone is not sufficient, because with a given signal, it is not possible to understand the level of aggregation compared to the initial state unless the measurement is compared against a standard range, which necessarily biases the measurement of the tested biological sample.

[0010] -TR-FRET (Time-Resolved Energy Transfer): Kits based on this method have been developed and are commercially available to detect the aggregation of TAU and alpha-synuclein in organic samples (see the Cisbio website, commercial references 6FTAUPEG and 6FASYPEG). These tests use identically labeled antibodies as fluorescent donors and acceptors, respectively. In the presence of PAFβ, the two labeled antibodies simultaneously bind to PAFβ for aggregation and induce energy transfer between the donor and fluorescent acceptor located close to each other. The acceptor antibody then emits a specific FRET signal, which is measured in time-resolved time. On the other hand, only one of the two antibodies may be bound to PAFβ, thus preventing any proximity between the donor and acceptor. This makes it impossible to obtain a FRET signal on PAFβ. These kits allow for the determination of the level of aggregation of PAFβ of interest and the effect of compounds on that level of aggregation in a miniaturized and rapid format. Nevertheless, these kits require the use of antibodies capable of recognizing epitopes of PAFβ even when said epitopes are aggregated, but immunization is generally performed with PAFβ, which can make it difficult to obtain anti-PAFβ antibodies, and this can limit or even hinder the development of detection tests.

[0011] Therefore, the method described in the prior art is particularly intended to directly detect PAFβ in sample by using one or more ligands of PAFβ.Nevertheless, directly detecting PAFβ may make these techniques difficult to carry out, inaccurate, and / or hardly suitable for large-scale use.In addition, detecting PAFβ alone is not sufficient, because with a given signal, it is not possible to understand the level of aggregation compared to the initial state unless measured value is compared with the standard range, which necessarily biases the measured value of the biological sample being tested. [Prior art documents] [Non-patent literature]

[0012] [Non-Patent Document 1] Harrison et al., RNA-binding proteins with prion-like domains in health and disease (2017) Biochem J.;474(8):1417-1438. doi:10.1042 / BCJ20160499 [Non-patent document 2] Chang et al., Detection and quantification of TAU aggregation using a membrane filter assay, Analytical Biochemistry 373 (2008) pp. 330-336 [Non-patent document 3] Howlett et al., Inhibition of fibril formation in b-amyloid peptide by a novel series of benzofurans, Biochem. J. (1999) 340, pp. 283-289 [Non-patent document 4] Linghagen-Persson et al., Amyloid-b Oligomer Specificity Mediated by the IgM Isotype - Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies, PLoS ONE, November 2010 | Volume 5 | Issue 11 | e13928 [Non-Patent Document 5] Englund et al., Sensitive ELISA detection of amyloid-b protofibrils in biological samples, Journal of Neurochemistry, 2007, 103, pp. 334-345 [Non-patent document 6] Van Helmond et al., Higher Soluble Amyloid b Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease, Brain Pathology ISSN 1015-6305, doi:10.1111 / j.1750-3639.2010.00374.x Summary of the Invention [Problem to be solved by the invention]

[0013] Therefore, there is a need for easier, faster and more reliable diagnosis of diseases associated with PFβ aggregation. [Means for solving the problem]

[0014] The applicant has developed a simple and easy-to-implement protocol that allows all or part of the PAFβ present in a sample to be disaggregated in order to obtain PNAFβ, which allows the applicant to develop a method for detecting PAFβ, carried out by measuring the PNAFβ content, which makes it possible to overcome all the limitations associated with the detection of PAFβ.

[0015] According to a first aspect, the present invention provides an in vitro method for detecting the β-sheet aggregate form of a protein that forms β-sheet aggregates (PAFβ) in a sample, comprising the following steps: a) In a first container: a1) placing a sample likely to contain PAFβ; a2) adjusting the pH to a range of 9.7 to 13.2 to disaggregate all or part of the PAFβ to obtain a β-sheet non-aggregated form of the protein that forms β-sheet aggregates (PNAFβ); a3) adjusting the pH to a pH in the range of 6 to 9; b) measuring the PNAFβ content in the first container using a suitable immunological method; c) in a second container: c1) adding the same sample as in step a1); c2) adjusting the pH to a pH in the range of 6 to 9; d) measuring the PNAFβ content in the second container using the same method as in step b); e) comparing the contents measured in steps b) and d), wherein a decrease in the content measured in step d) compared to the content measured in step b) indicates that the sample contains PAFβ. The present invention relates to a method, including:

[0016] According to a second aspect, the present invention provides an in vitro method for monitoring the therapeutic efficacy of a treatment of a disease associated with PAFβ, comprising the following steps: A) carrying out the method according to the invention on a first sample, in which step e) consists of determining the ratio between the content measured in step b) and the content measured in step d) ("ratio b) / d) of sample 1"); B) performing the same method as in step A) on a second sample to determine the "ratio b) / d) of sample 2"; C) Comparing the ratios determined in steps A) and B), and observing therapeutic efficacy when the ratio determined in step B) is lower than the ratio determined in step A). The present invention relates to a method comprising:

[0017] According to a third aspect, the present invention provides an in vitro method for determining the pharmacological efficacy of a molecule for a disease associated with PAFβ, comprising the following steps: A) carrying out the method according to the invention on a first sample, in which step e) consists of determining the ratio between the content measured in step b) and the content measured in step d) ("ratio b) / d) of sample 1"); B) performing the same method as in step A) on a second sample to determine the "ratio b) / d) of sample 2"; C) comparing the ratios determined in steps A) and B), and observing pharmacological efficacy if the ratio determined in step B) is lower than the ratio determined in step A). The present invention relates to a method, including: [Brief explanation of the drawings]

[0018] [Figure 1] Figure 1 illustrates the general principle of the method according to the present invention. Thus, by comparing the PAFβ levels (signal ratio), it is possible to know whether the tested sample contains PAFβ. The signal ratio of a sample that does not contain PAFβ will be equal to 1. The signal ratio of a sample that contains PAFβ will be greater than 1. [Figure 2] Figure 2 shows the resulting ELISA signal (OD) for various dilutions of PNAFβ. The OD value corresponding to 80% of the maximum signal is used to determine the reference dilution to be used in the remainder of the experiment. [Figure 3] Figure 3 shows the results obtained in an ELISA test aimed at determining whether pairs of antibodies selectively recognize PNAFβ: A) Pair of antibodies that are non-selective for PNAFβ; B) Pair of antibodies that are selective for PNAFβ. [Figure 4] Figure 4 shows the principle of HTRF immunoassay. This type of immunoassay makes it possible to determine whether two antibodies, each labeled with a donor and an acceptor, can form a pair of antibodies capable of simultaneously recognizing the antigen of interest. A) The two tested antibodies cannot form a pair of antibodies capable of recognizing the antigen of interest; there is no energy transfer between the donor and acceptor, and therefore no fluorescent signal is emitted by the acceptor. B) The two tested antibodies can simultaneously recognize the antigen of interest. Energy transfer then occurs between the donor and acceptor, resulting in a specific fluorescent emission at 665 nm emitted by the acceptor. [Figure 5]Figure 5 shows the HTRF signals obtained for various dilutions of PNAFβ. The HTRF signal value corresponding to 80% of the maximum signal is used to determine the reference dilution to be used in the remainder of the experiment. [Figure 6] Figure 6 shows the results obtained in an HTRF study aimed at determining whether antibody pairs selectively recognize PNAFβ: A) PNAFβ non-selective antibody pair; B) PNAFβ selective antibody pair. [Figure 7] 7 shows the calculation of the signal ratio between a TDP-43 AFβ aggregate sample and a TDP-43 NAFβ monomer sample obtained using a pair of antibodies directed against the TDP-43 protein. A signal ratio greater than 2 indicates that the tested pair is selective for TDP-43 NAFβ. [Figure 8] 8 shows the calculation of the signal ratio between an aggregate sample of beta 1-40 amyloid peptide and a monomeric sample of this same peptide obtained using a pair of antibodies directed against the beta 1-40 amyloid peptide. A signal ratio value greater than 2 indicates that the tested pair is selective for the 1-40 amyloid peptide NAFβ (monomeric form). [Figure 9] 9 shows the calculation of the signal ratio between an aggregate sample of beta 1-42 amyloid peptide and a monomeric sample of this same peptide obtained using a pair of antibodies directed against the beta 1-42 amyloid peptide. A signal ratio value greater than 2 indicates that the tested pair is selective for the 1-42 amyloid peptide NAFβ (monomeric form). [Figure 10] FIG. 10 shows the effect of hexafluoroisopropanol (HFIP) on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 11] FIG. 11 shows the lack of disruptive effect of hexafluoroisopropanol (HFIP) on samples of TDP-43 AFβ. [Figure 12]FIG. 12 shows the effect of urea on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 13] FIG. 13 shows the lack of disruptive effect of urea on samples of TDP-43 AFβ. [Figure 14] FIG. 14 shows the effect of guanidinium chloride on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 15] FIG. 15 shows the effect of formic acid (A) or TFA (B) on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 16] FIG. 16 shows the effect of formic acid followed by neutralization with NaOH on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 17] FIG. 17 shows the effect of TFA followed by neutralization with NaOH on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 18] FIG. 18 shows the lack of disruptive effect of TFA followed by neutralization with NaOH on samples of TDP-43 AFβ. [Figure 19] FIG. 19 shows the effect of formic acid followed by neutralization with NH 4 OH on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 20] FIG. 20 shows the lack of disruptive effect of formic acid followed by neutralization with NH 4 OH on a sample of TDP-43 AFβ. [Figure 21] FIG. 21 shows the effect of TFA followed by neutralization with NH 4 OH on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 22]FIG. 22 shows the lack of disruptive effect of TFA followed by neutralization with NH 4 OH on a sample of TDP-43 AFβ. [Figure 23] FIG. 23 shows the effect of NaOH solutions providing pH values ​​comprised between 8.2 and 13.3, followed by neutralization with HCl, on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 24] FIG. 24 shows the determination of the minimum and maximum pH for disaggregating samples of TDP-43 AFβ using NaOH solution. [Figure 25] FIG. 25 shows the determination of the time required to disaggregate a sample of TDP-43 AFβ using a solution of NaOH at pH=12.8. [Figure 26] FIG. 26 shows the determination of minimum and maximum pH when measuring the detection of TDP-43 NAFβ. [Figure 27] FIG. 27 shows the measurement of the level of aggregation of beta 1-42 amyloid peptide using NaOH as a disaggregating agent followed by neutralization with HCl. [Figure 28] FIG. 28 shows the effects of NaOH, KOH, and NH 4 OH solutions, followed by HCl neutralization, on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ. [Figure 29] FIG. 29 shows the effect of NaOH, KOH, and NH 4 OH solutions followed by neutralization with HCl on the disaggregation of TDP-43 NAFβ. [Figure 30] Figure 30 shows the calculation of the signal ratio between an aggregate sample of alpha-synuclein (Alpha-Syn AFβ) and a monomeric sample of this same protein (Alpha-Syn NAFβ) obtained using a pair of antibodies directed against alpha-synuclein. A signal ratio value greater than 2 indicates that the tested pair is selective for Alpha-Syn NAFβ. [Figure 31]FIG. 31 shows the effect of NaOH solution followed by neutralization with HCl on the detection ability of the HTRF method using a pair of antibodies capable of specifically binding to Alpha-Syn NAFβ. [Figure 32] FIG. 32 shows the measurement of the level of aggregation of alpha-synuclein using NaOH as a disaggregating agent followed by neutralization with HCl. DETAILED DESCRIPTION OF THE INVENTION

[0019] definition The term "β-sheet aggregate-forming protein" or "PFβ" refers to a protein capable of forming β-sheet-rich aggregates, i.e., a protein capable of forming β-sheet-rich multimeric (or oligomeric) forms. While the non-aggregated form of PFβ is generally normal, its aggregated form is particularly associated with neurodegenerative diseases, such as Alzheimer's disease, Creutzfeldt-Jakob disease, Parkinson's disease, or amyotrophic lateral sclerosis (ALS). The protein may be native or recombinant, either human or animal. In the context of the present invention, the non-aggregated form of PFβ is referred to as "β-sheet non-aggregated form of β-sheet aggregate-forming protein" or "PNAFβ." The aggregated form of PFβ is referred to as "β-sheet aggregate-forming form of β-sheet aggregate-forming protein" or "PAFβ."

[0020] PFβ may be in an aggregated form (PAFβ) or a non-aggregated form (PNAFβ) and may be selected from FUS (Fused in sarcoma), TAF15, EWSR1, DAZAP1, TIA-1, TTR (Transthyretin), Cystatin C, β2-microglobulin, β-amyloid peptide (such as β1-40 amyloid peptide or β1-42 amyloid peptide), TAU (Tubulin-Associated Unit), α-synuclein, β-synuclein, γ-synuclein, Huntingtin (HTT), SOD1 (Superoxide dismutase 1), prion, and TDP-43 (TAR DNA-binding protein 43). For example, if PFβ is TDP-43, then "TDP-43 NAFβ" is considered to be the non-aggregated form of TDP-43, and "TDP-43 AFβ" is considered to be the aggregated form of TDP-43.

[0021] The PFβ proteins listed above are particularly involved in neurodegenerative diseases, such as FUS, TAF15, beta-amyloid peptides, Alzheimer's disease and hereditary cerebral amyloid angiopathy, prions, Creutzfeldt-Jakob disease and spongiform encephalopathies, alpha-synuclein, Parkinson's disease, TAU proteins, Alzheimer's disease and frontotemporal dementia, transthyretin, senile systemic amyloidosis or familial amyloid polyneuropathy, cystatin C, hereditary cerebral amyloid angiopathy, beta-2-microglobulin, hemodialysis-associated amyloidosis, huntingtin, Huntington's disease, SOD1, and TDP-43, which are involved in amyotrophic lateral sclerosis and frontotemporal dementia. Preferably, PFβ is selected from β1-42 amyloid peptide, β1-40 amyloid peptide, α-synuclein or TDP-43.

[0022] The sample on which the method of the present invention is carried out may be any sample likely to contain at least one PAFβ, and may be a biological sample of human or animal origin or a sample of cells or tissues cultured in vitro.

[0023] The term "in vitro method" means a method performed outside the human or animal body, for example, on a microorganism, an organ, a tissue, a cell, a cell subfraction (e.g., nucleus, mitochondria) or a protein (natural or recombinant). The term "in vitro" includes ex vivo.

[0024] The sample may be derived from an individual, human or animal, who has or is suspected to have a disease associated with PAFβ, such as a neurodegenerative disease as described above. For example, the sample may be selected from a blood sample, a plasma sample, a serum sample, or a cerebrospinal fluid sample. The sample may also be prepared from tissues or cells obtained from an individual, such as the brain, central nervous system tissue, organs such as the spleen and intestine. Thus, the sample may be a cell lysate, a cell homogenate, a tissue lysate, or a tissue homogenate, such as a brain homogenate. The sample may also include cells (e.g., cell lines), cell subfractions (e.g., nuclei, mitochondria), or (natural or recombinant) proteins.

[0025] The sample may also be derived from in vitro or ex vivo cultured cells or tissues, preferably from a cell or tissue model of a disease associated with PAFβ. For example, the sample may be selected from a cell lysate, cell homogenate, tissue lysate, tissue homogenate, cell culture supernatant, or tissue culture supernatant.

[0026] Preferably, the sample is a cell lysate or a cell homogenate.

[0027] The term "vessel" refers to a well of a plate, a test tube or any other container suitable for mixing a sample with reagents necessary for carrying out the method according to the invention.

[0028] Within the meaning of the present invention, the term "ligand" refers to a molecule capable of binding to a target molecule. In the context of the present invention, the target molecule is PNAFβ. It is therefore called a "ligand of PNAFβ". The ligand may be proteinaceous (e.g., protein or peptide) or nucleotide (e.g., DNA or RNA). In the context of the present invention, the ligand is advantageously selected from an antibody, an antibody fragment, a peptide or an aptamer, preferably an antibody or an antibody fragment.

[0029] Within the meaning of the present invention, the terms "ligand capable of specifically binding to PNAFβ" or "pair of ligands capable of specifically binding to PNAFβ" refer to a ligand or pair of ligands that preferentially binds to PNAFβ with respect to PAFβ, i.e., a ligand or pair of ligands that can generate, with at least one PNAFβ, a signal (e.g., an ELISA signal or a RET signal) that is two-fold higher, for example, at least three, at least four, at least five, or at least six-fold higher than the signal generated with the corresponding PAFβ. Examples 1 to 4 and 25 of the present application describe ELISA and FRET methods that allow easily determining whether a ligand or pair of ligands is capable of specifically binding to PNAFβ.

[0030] Advantageously, a "ligand capable of specifically binding to PNAFβ" or a "pair of ligands capable of specifically binding to PNAFβ" can bind to PNAFβ with an affinity that is at least two times greater than the affinity for the corresponding PAFβ, for example, at least two times greater, at least three times greater, at least four times greater, at least five times greater, at least six times greater, at least seven times greater, at least eight times greater, at least nine times greater, or at least ten times greater than the affinity for the corresponding PAFβ. In the case of a pair of ligands capable of specifically binding to PNAFβ, it is not necessary for the two ligands of the pair of ligands to be specific for PNAFβ. In fact, for a pair of ligands to be specific for PNAFβ, it is sufficient that at least one of the two ligands of the pair of ligands is a ligand specific for PNAFβ. Nevertheless, both ligands of the pair of ligands may be ligands specific for PNAFβ.

[0031] The term "affinity" refers to the strength of all non-covalent interactions between a ligand and an antigen. Affinity is usually expressed by dissociation constant (Kd). The lower the Kd value, the higher the binding affinity between the ligand and its target. Dissociation constant (Kd) can be measured by well-known methods, for example, by FRET, ELISA, or SPR. Therefore, the techniques described in the literature make it easy to know whether a ligand or a pair of ligands is specific for PNAFβ.

[0032] The term "antibody," also known as "immunoglobulin," refers to a heterotetramer consisting of two heavy chains (H chains) of approximately 50-70 kDa each and two light chains (L chains) of approximately 25 kDa each, linked together by intra- and inter-chain disulfide bridges. Each chain is composed of a variable region or domain at the N-terminus, designated VL for the light chain and VH for the heavy chain, and a constant region at the C-terminus, consisting of a single domain designated CL for the light chain and three or four domains designated CH1, CH2, CH3, and CH4 for the heavy chain. Each variable domain generally contains four "hinge regions" (designated FR1, FR2, FR3, and FR4) and three regions directly involved in binding to the antigen, designated "CDRs" (designated CDR1, CDR2, and CDR3). "Antibodies" may be of mammalian (e.g., human, mouse, rat, or camelid) origin, humanized, chimeric, or recombinant. Preferably, the antibody is a monoclonal antibody recombinantly produced by genetically modified cells according to techniques well known to those skilled in the art. The antibody can be of any isotype, for example, IgG, IgM, IgA, IgD or IgE, preferably IgG.

[0033] The term "antibody fragment" refers to any portion of an immunoglobulin, obtained by enzymatic digestion or biological production, that contains at least one disulfide bridge and is capable of binding to an antigen recognized by a whole antibody, such as Fv, Fab, Fab', Fab'-SH, F(ab')2, diabody, linear antibody (also called "single domain antibody" or sdAb, or nanobody), or single-chain antibody (e.g., scFv). Enzymatic digestion of immunoglobulins with pepsin produces F(ab')2 and Fc fragments, which are separated into several peptides. F(ab')2 is composed of two Fab' fragments linked by interchain disulfide bridges. The Fab portion consists of the variable region and the CH1 and CL domains. The Fab' fragment consists of the Fab region and hinge region. Fab'-SH refers to a Fab' fragment in which the cysteine ​​residue in the hinge region has a free thiol group.

[0034] The term "tracer" refers to a chemical or biological substance capable of directly or indirectly emitting a signal that can be detected using an appropriate detection device. It can be a fluorescent, luminescent, radioactive, or enzymatic tracer. In certain embodiments, the tracer is a member of a RET partner pair.

[0035] The term "RET" (from "resonance energy transfer") refers to an energy transfer technique. RET can be FRET or BRET.

[0036] The term "FRET" (from "fluorescence resonance energy transfer") refers to the transfer of energy between two fluorescent molecules. FRET is defined as non-radiative energy transfer due to dipole-dipole interactions between an energy donor and an energy acceptor. This physical phenomenon requires energy compatibility between these molecules, which means that the emission spectrum of the donor must at least partially overlap the absorption spectrum of the acceptor. Consistent with Förster's theory, FRET is a process that depends on the distance separating the two molecules, donor and acceptor: when these molecules are close to each other, a FRET signal is emitted.

[0037] The term "BRET" (from "bioluminescence resonance energy transfer") refers to the transfer of energy between a bioluminescent molecule and a fluorescent molecule.

[0038] The term "RET partner pair" refers to a pair consisting of an energy donor compound (hereinafter "donor compound") and an energy acceptor compound (hereinafter "acceptor compound"), which emit a RET signal when brought into close proximity and excited at the excitation wavelength of the donor compound. It is known that for two compounds to be RET partners, the emission spectrum of the donor compound must partially overlap with the excitation spectrum of the acceptor compound. For example, this is the case for a "FRET partner pair" when a fluorescent donor compound and an acceptor compound are used, or a "BRET partner pair" when a donor bioluminescent compound and an acceptor compound are used.

[0039] The term "RET signal" refers to any measurable signal representative of RET between a donor compound and an acceptor compound. Thus, for example, a FRET signal can be a fluctuation in intensity or emission lifetime of a donor fluorescent compound or an acceptor compound, if the latter is fluorescent.

[0040] <<Two Containers>> Detection Method According to a first aspect, the present invention provides an in vitro method for detecting the β-sheet aggregate form of a protein that forms β-sheet aggregates (PAFβ) in a sample, comprising the following steps: a) In a first container: a1) placing a sample likely to contain PAFβ; a2) adjusting the pH to a range of 9.7 to 13.2 to disaggregate all or part of the PAFβ to obtain a β-sheet non-aggregated form of the protein that forms β-sheet aggregates (PNAFβ); a3) adjusting the pH to a pH in the range of 6 to 9; b) measuring the PNAFβ content in the first container using a suitable immunological method; c) in a second container: c1) adding the same sample as in step a1); c2) adjusting the pH to a pH in the range of 6 to 9; d) measuring the PNAFβ content in the second container using the same method as in step b); e) comparing the contents measured in steps b) and d), wherein a decrease in the content measured in step d) compared to the content measured in step b) indicates that the sample contains PAFβ. The present invention relates to a method comprising:

[0041] The general principle of the method according to the invention is illustrated in FIG.

[0042] The method is described in detail step by step below. Step a) Step a1) comprises placing a sample likely to contain PAFβ in a first container. The sample can be prepared in advance so that the steps of the method, in particular the step of measuring the PNAFβ content, can be carried out appropriately. For example, if the sample is tissue or cells, it can be prepared in advance by dissolving, grinding, filtering and / or decomposing in a suitable solvent, such as water. Those skilled in the art will have no difficulty in preparing the sample.

[0043] Step a2) consists of adjusting the pH to a range of 9.7 to 13.2 in order to disaggregate all or part of PAFβ to obtain the β-sheet non-aggregated form of the protein (PNAFβ) that forms β-sheet aggregates. The Applicant has found that a pH in the range of 9.7 to 13.2 actually makes it possible to disaggregate PAFβ. This disaggregation phenomenon makes it possible to obtain PNAFβ from PAFβ.

[0044] This phenomenon of disaggregation at pH values ​​in the range of 9.7–13.2 is quite surprising, since disaggregation methods described in the prior art consist of treating PNAFβ with strong detergents at rather acidic pH and / or by sonication. For example, the work described in [7] demonstrates various methods for obtaining relatively monomeric amyloid protein from amyloid fibrils. In the first approach, amyloid fibril preparations are treated with an acid, 88% formic acid, in combination with a strong detergent-type detergent, sodium dodecyl sulfate (SDS). An alternative method involves combining a saturated solution (6.8 M) of the chaotropic agent guanidine thiocyanate with SDS. In both cases, the authors noted the disappearance of amyloid fibrils in favor of relatively monomeric amyloid protein (a mixture of monomers and dimers). Another study [8] described a different method for treating biological samples to disaggregate the amyloid protein (β1-42 amyloid peptide) they contain and then assaying them using an ELISA test. Mouse brain extracts or patient cerebrospinal fluid were treated with a solution of fluorinated alcohol (HFIP) or trifluoroacetic acid (TFA) combined with 15 minutes of sonication to disaggregate the amyloid protein. The HFIP or TFA was then removed by drying under a constant stream of nitrogen. The dried sample containing the disaggregated amyloid protein was then dissolved in a 1% NH4OH solution and subsequently analyzed. The authors suggested that these two treatments could disaggregate β1-42 amyloid peptide aggregates, thereby improving their quantification.

[0045] Nevertheless, the applicant has shown that the disaggregation methods described in the prior art do not allow for the measurement of PNAFβ content using immunological methods that require performance at physiological pH (see Examples 5-17).

[0046] The method of the present invention does not require treatment at an acidic pH to disaggregate PAFβ. On the contrary, the applicant has not only demonstrated that PAFβ could be disaggregated by treatment at a pH in the range of 9.7 to 13.2, but also demonstrated that this treatment was fully compatible with subsequent immunological methods aimed at measuring the PNAFβ content.

[0047] Advantageously, step a2) consists of adjusting the pH to a pH in the range 10-13.2, for example a pH in the range 11-13.2, a pH in the range 11.5-13.2, a pH in the range 12-13.2, a pH in the range 12.5-13.2, a pH in the range 12.8-13.2, a pH in the range 10-13, a pH in the range 11-13, a pH in the range 12-13, for example about 12.8.

[0048] The pH is adjusted using a base, for example a strong base such as KOH or NaOH, preferably NaOH.

[0049] The duration of step a2) can vary depending on various parameters, such as the base or PFβ used. In particular, step a2) can last at least 30 seconds, for example, at least 1 minute, at least 2 minutes, at least 5 minutes, at least 10 minutes, or at least 15 minutes, for example, between 30 seconds and 60 minutes, or between 5 minutes and 30 minutes. Those skilled in the art will have no difficulty adapting the duration of step a2) to manage the disaggregation of all or part of PAFβ to obtain PNAFβ.

[0050] Step a3) consists of adjusting the pH to a pH in the range of 6 to 9. This step is important because it makes it possible to carry out the immunological method of step b).

[0051] Advantageously, step a3) consists of adjusting the pH to a pH in the range 6.4 to 9, for example to a pH in the range 6.4 to 8.4, to a pH in the range 6 to 8.5, to a pH in the range 7 to 8.5.

[0052] The pH is adjusted using an acid, for example, a strong acid, such as HCl.

[0053] Step b) Step b) consists of measuring the PNAFβ content in the first container using a suitable immunological method (or suitable "immunoassay").

[0054] The immunological method of step b) must make it possible to obtain contents that are comparable to one another. However, the immunological method in step b) does not have to be quantitative, although it may be. The immunological method of step b) must at least make it possible to determine a relative content, which can be compared with another relative content determined by the same immunological method.

[0055] In certain embodiments, the immunological method carried out in step b) comprises: (i) a ligand capable of specifically binding to PNAFβ, the ligand being labeled with a tracer; or (ii) a pair of ligands capable of specifically binding to PNAFβ, wherein at least one ligand of the pair of ligands is labeled with a tracer; Use.

[0056] The ligand (i) may be selected from an antibody, an antibody fragment, a peptide or an aptamer, preferably an antibody. The pair of ligands (ii) may be selected from a pair of antibodies, a pair of antibody fragments, a pair of peptides or a pair of aptamers, preferably a pair of antibodies.

[0057] Those skilled in the art will have no difficulty in obtaining and / or selecting antibodies or antibody fragments with desired properties, for example, by immunizing mice with PFβ, performing lymphocyte hybridization from splenic lymphocytes of the immunized mice to generate hybridomas, and testing the antibodies of each hybridoma for their ability to specifically bind to PNAFβ. Examples of complete protocols for generating anti-PNAFβ antibodies and then selecting specific antibodies are detailed in Examples 1-4 and 25. Therefore, for example, by carrying out the methods described in Examples 1-4 and 25, it is extremely easy to obtain an antibody or antibody pair against any PNAFβ for carrying out the method of the present invention.

[0058] Obtaining PNAFβ and PAFβ is within the understanding of those skilled in the art. For example, for proteins known as "prion-like" proteins, such as TDP-43, FUS, TAF15, and EWSR1, fusion of these proteins to glutathione-S-transferase (GST) (N- or C-terminal fusion depending on the protein) allows for the production of GST fusion proteins, the turbidimetric analysis of which shows that they are in a non-aggregated form [9]

[10]

[13] . When a tobacco etch virus protease (TEV) cleavage site is inserted between the target PFβ and GST, treatment of the GST protein with TEV followed by a purification step allows for the production of GST proteins without labeling. When the proteins are left at room temperature with agitation for 1 hour and 30 minutes, turbidimetric analysis shows that they are in an aggregated form

[10]

[13] . PFβ fused to GST is also commercially available, for example from Abnova: GST-TDP-43 (reference H00023435-P02), GST-FUS1 (reference H00002521-P01), GST-TAF15 (reference H00008148-P02), GST-EWSR1 (reference H00002130-Q01).

[0059] Amyloid peptides, particularly the β1-40 and β1-42 forms, are also available in powder form from numerous suppliers. Solubilization of these powders with HFIP or NH4OH allows for the preparation of stock solutions containing more than 90% of the non-aggregated form. Pre-dilution of these solutions with a buffer at physiological pH allows for the preparation of samples in non-aggregated form. Conversely, incubation of these same stock solutions for several hours to several days, e.g., more than 24 hours at room temperature in a physiological buffer, allows for the preparation of samples containing a very high proportion of the aggregated form

[11] .

[0060] Samples containing PNAFβ and PAFβ can also be obtained from StressMarq (www.stressmarq.com), in particular for alpha-, beta-, and gamma-synuclein, TAU protein, Cu / Zn superoxide dismutase 1 (SOD1) protein, or transthyretin (TTR).

[0061] Advantageously, the immunological method carried out in step b) is an ELISA method or an RET method, such as FRET or BRET.

[0062] Depending on the method used, the measurement in step b) can be carried out directly in the first container by adding appropriate reagents, or in a separate container that contains all or part of the contents of the first container. For example, the reagents for the RET method can be added directly to the first container. Conversely, the ELISA method is preferably carried out in a separate container that is suitable for carrying out the ELISA method, in particular in a container on the bottom of which the PNAFβ ligand is pre-immobilized.

[0063] In certain embodiments, step b) is carried out by the RET method, (b1) placing in a container a first PNAFβ ligand labeled with a first member of a RET partner pair and a second PNAFβ ligand labeled with a second member of a RET partner pair, wherein the pair of ligands are capable of specifically binding to PNAFβ; and (b2) measuring the emitted RET signal in the container It consists of:

[0064] For the RET method to be implemented, the first and second ligands must not compete for binding to PNAFβ, e.g., they must not bind to the same epitope on PNAFβ. It is easy to select an appropriate pair of ligands by implementing the methods described in Examples 1-4 and 25.

[0065] The ligand can be directly or indirectly labeled. Direct labeling of the ligand with a member of a RET partner pair can be performed by conventional methods known to those skilled in the art based on the presence of reactive groups on the ligand. For example, if the ligand is an antibody or antibody fragment, the following reactive groups can be used: terminal amino group, carboxylate groups of aspartic acid and glutamic acid, amine group of lysine, guanidine group of arginine, thiol group of cysteine, phenol group of tyrosine, indole ring of tryptophan, thioether group of methionine, imidazole group of histidine.

[0066] The reactive group can form a covalent bond with a reactive group carried by a member of a RET partner pair. Suitable reactive groups carried by members of a RET partner pair are well known to those skilled in the art; for example, a donor or acceptor compound functionalized with a maleimide group can be covalently bonded to a thiol group carried by a cysteine ​​carried by a protein or peptide, such as an antibody or antibody fragment. Similarly, a donor / acceptor compound carrying an N-hydroxysuccinimide ester can be covalently bonded to an amine present on a protein or peptide.

[0067] The ligand can also be indirectly labeled with a fluorescent or bioluminescent compound, for example, by introducing an antibody or antibody fragment into the measurement medium which is itself covalently bound to an acceptor / donor compound, and this second antibody or antibody fragment specifically recognizes the ligand.

[0068] Another very conventional means of indirect labeling consists of attaching biotin to the ligand to be labeled and then incubating this biotinylated ligand in the presence of streptavidin labeled with an acceptor / donor compound. Suitable biotinylated ligands can be prepared by techniques well known to those skilled in the art; Cisbio Bioassays, for example, markets streptavidin labeled with a fluorophore under the trade name "d2" (reference 610SADLA).

[0069] Advantageously, one member of the RET partner pair is a fluorescent or luminescent donor compound and the other member of the RET partner pair is a fluorescent or non-fluorescent acceptor compound (quencher).

[0070] When RET is FRET, the donor fluorescent compound can be a FRET partner selected from europium cryptate, europium chelate, terbium chelate, terbium cryptate, ruthenium chelate, quantum dot, allophycocyanin, rhodamine, cyanine, squaraine, coumarin, proflavine, acridine, fluorescein, boron-dipyrromethene derivative, and nitrobenzoxadiazole.When RET is FRET, the acceptor fluorescent compound can be a FRET partner selected from allophycocyanin, rhodamine, cyanine, squaraine, coumarin, proflavine, acridine, fluorescein, boron-dipyrromethene derivative, nitrobenzoxadiazole, quantum dot, GFP, GFP10, GFP2, and eGFP, YFP, eYFP, YFP Topaz, YFP Citrine, YFP Venus, and YPet, mOrange, and DsRed.

[0071] When RET is BRET, the donor luminescent compound can be a BRET partner selected from luciferase (luc), Renilla luciferase (Rluc), a Renilla luciferase variant (Rluc8), and firefly luciferase.When RET is BRET, the acceptor fluorescent compound is a BRET partner selected from allophycocyanin, rhodamine, cyanine, squaraine, coumarin, proflavine, acridine, fluorescein, boron-dipyrromethene derivative, nitrobenzoxadiazole, quantum dot, GFP, GFP10, GFP2, and eGFP, a GFP variant selected from YFP, eYFP, YFP Topaz, YFP Citrine, YFP Venus, and YPet, mOrange, and DsRed.

[0072] In certain embodiments, step b) is performed by ELISA, (b1) placing all or a portion of the sample into a container having a first PNAFβ ligand immobilized on the bottom thereof, and then placing a second PNAFβ ligand labeled with a tracer therein, the pair of ligands being capable of specifically binding to PNAFβ; (b2) measuring the emitted ELISA signal in the vessel It consists of:

[0073] The ELISA method has been widely described in the prior art and presents no difficulty to the skilled artisan in carrying it out.

[0074] Step c) Step c) comprises placing in a first container a sample c1) identical to step a1).

[0075] Contrary to step a), the pH is adjusted during step c) to a pH in the range of 9.7 to 13.2. The pH is adjusted directly to a pH in the range of 6 to 9 (step c2)), preferably to a pH identical to the pH of step a3).

[0076] The pH of step c2) can be adjusted using an acid / base mixture, such as a strong acid / strong base mixture, such as a NaOH / HCl mixture. Preferably, the acid used in step c2) is the same as that used in step a3), and the base used in step c2) is the same as that used in step a2).

[0077] Step d) Step d) comprises measuring the PNAFβ content in the second container using the same method as step b), which can be carried out in the same manner as step b), comparing the measurements, and carrying out step e).

[0078] Thus, if step b) is carried out by the RET method, step d) comprises: (d1) placing in a container a first PNAFβ ligand labeled with a first member of a RET partner pair and a second PNAFβ ligand labeled with a second member of a RET partner pair, wherein the pair of ligands are capable of specifically binding to PNAFβ; and (d2) measuring the emitted RET signal in the container It consists of:

[0079] In the same method, when step b) is carried out by ELISA, step d) comprises: (d1) placing all or a part of the sample into a container having a first PNAFβ ligand immobilized on the bottom, and then placing a second PNAFβ ligand labeled with a tracer, the pair of ligands being capable of specifically binding to PNAFβ; (d2) measuring the emitted ELISA signal in the vessel It consists of:

[0080] Step e) Step e) consists of comparing the contents measured in step b) and in step d), and a decrease in the content measured in step d) compared to the content measured in step b) indicates that the sample contains PAFβ.

[0081] If the first and second containers are exchanged, it is clear that step e) consists of comparing the contents measured in step b) and in step d), and an increase in the content measured in step d) compared to the content measured in step b) indicates that the sample contains PAFβ.

[0082] Those skilled in the art can easily compare the contents measured in steps b) and d) and define a threshold value that allows for identifying an increase or decrease. For example, the difference between the measured contents is greater than 5%, greater than 10%, greater than 15%, greater than 20%, or greater than 25%. The determination of the threshold value may vary depending on the variability inherent in the selected immunological method.

[0083] A person skilled in the art will be able to calculate, for example, the ratio between the contents measured in steps b) and d). Generally, the greater the difference between the measured contents, the greater the ratio between the measured contents and the greater the amount of PAFβ in the sample.

[0084] If the immunological method is an ELISA or RET method, the RET signal or ELISA signal measured in step b) and step d) are compared.Therefore, a decrease in the RET signal or a decrease in the ELISA signal indicates that the sample contains PAFβ.Advantageously, a ratio is calculated between the signal measured in the first container (step b)) and the signal measured in the second container (step d)).The calculation of the ratio can be performed manually or automatically.

[0085] Preferably, the period between step a3) and step b) and / or step c2) and step d) is adapted to prevent PNAFβ from reaggregating into PAFβ. The period is preferably less than 24 hours, for example less than 5 hours. Advantageously, steps b) and d) are performed subsequent to steps a3) and c2), respectively, i.e., less than 30 minutes after steps a3) and c2). Those skilled in the art will have no difficulty in adapting the period of step a3) and / or step c2) to prevent all or part of PNAFβ from reaggregating into PAFβ before step c) and / or step d).

[0086] The comparison of the contents in the two samples in step e) makes it possible to measure the level of aggregation very accurately, especially compared to most methods of the prior art.

[0087] Methods for monitoring therapeutic efficacy The present invention also provides an in vitro method for monitoring the therapeutic efficacy of a treatment for a disease associated with PAFβ in a patient, comprising the steps of: A) carrying out the method according to the invention on a first sample of said patient, in which step e) consists in determining the ratio between the content measured in step b) and the content measured in step d) ("ratio b) / d) of sample 1"); B) performing the same method as in step A) on a second sample from said patient to determine the "ratio b) / d) of sample 2"; C) Comparing the ratios determined in steps A) and B), and observing therapeutic efficacy when the ratio determined in step B) is lower than the ratio determined in step A). The present invention relates to a method, including:

[0088] The treatment can be a known or experimental treatment for a disease associated with PAFβ.The sample is preferably derived from an individual with a PAFβ-related disease.

[0089] In order to be able to monitor the effectiveness of treatment, the first sample and the second sample are taken from the patient at different time points, for example, the first sample is taken at time T1, and the second sample is taken at time T2.Advantageously, the first sample is taken before the second sample, for example, the first sample is taken at time T1, before or during the treatment of the patient, and the second sample is taken at time T2, after or during the treatment.The time that passes between the collection of the first sample and the collection of the second sample is selected so that the therapeutic effectiveness of treatment can be detected.

[0090] Methods for monitoring measurements of pharmacological efficacy The present invention also provides an in vitro method for determining the pharmacological efficacy of a drug molecule or drug candidate against a disease associated with PAFβ in a test sample, comprising the steps of: A) carrying out the method according to the invention on a first sample of said test samples, wherein step e) consists in determining the ratio between the content measured in step b) and the content measured in step d) ("ratio b) / d) of sample 1"); B) performing the same method as in step A) on a second sample of the test sample to determine the "ratio b) / d) of sample 2"; C) comparing the ratios determined in steps A) and B), and observing pharmacological efficacy if the ratio determined in step B) is lower than the ratio determined in step A). The present invention relates to a method, including:

[0091] The molecule can be a drug or a drug candidate.The sample is preferably derived from cells or tissues cultured in vitro.As a result, the drug molecule or drug candidate is preferably tested in an in vitro model of the disease associated with PAFβ.Such models are widely described in the literature.

[0092] The test sample corresponds to a sample that allows testing of drugs or drug candidates in vitro, and can be, for example, a sample of cells cultured in vitro or a sample of tissue cultured in vitro. The test sample corresponds to what is commonly referred to as an "in vitro model of a disease associated with PAFβ." Therefore, in order to measure the pharmacological effectiveness of a drug molecule or drug candidate, the first sample and the second sample are collected from the test sample at different time points, for example, the first sample is collected at time T1, and the second sample is collected at time T2. Advantageously, the first sample is collected before the second sample, for example, the first sample is collected at time T1 before treating the test sample with a drug molecule or drug candidate, and the second sample is collected at time T1 after said treatment. The time elapsed between collecting the first sample and the second sample is selected so as to be able to detect the pharmacological effectiveness of a drug molecule or drug candidate. [Example]

[0093] The invention will now be illustrated by the following non-limiting examples.

[0094] Example 1 Methods for identifying antibodies specific to PNAFβ

[0095] Preparation of anti-PNAFβ antibody Mouse immunization BALB / c mice were immunized with PNAFβ protein pre-diluted in phosphate buffer under physiological conditions. The presence or absence of PNAFβ multimers or aggregates was confirmed in the buffer intended for injection to direct the mouse immune response toward the non-aggregated form. The first injection was followed by three booster injections at monthly intervals.

[0096] Fifteen days after each injection, a blood puncture is performed on the mice and the presence of an immune response is confirmed by antibody titration.

[0097] Titer determination of immune serum for anti-PNAFβ antibodies by ELISA test For this purpose, an ELISA-type immunodetection test is performed depending on the nature of PFβ. For amyloid PFβ or peptides, PNAFβ is pre-labeled at its primary lysine with biotin using a reagent consisting of biotin, a carbon linker, and an NHS (N-hydroxysuccinimide) reactive group. For non-amyloid or amyloid PFβ, PNAFβ in GST fusion is directly immobilized on a 96-well plate via the GST tag using an ELISA microplate functionalized with glutathione groups. The biotin-labeled protein is immobilized on a 96-well ELISA plate via biotin using a microplate functionalized with streptavidin. For this purpose, 100 μl of GST fusion and / or biotinylated PNAFβ solution is added to each well and then incubated for 2 hours at room temperature. The wells are then washed three times with PBS buffer supplemented with 0.05% Tween-20. After removing the wash solution, each well is then incubated overnight at 4° C. with 200 μL of blocking solution composed of PBS, 5% BSA.

[0098] Then, 100 μL of serial dilutions of blood samples (immune serum) were added in duplicate in PBS + 0.1% BSA buffer at a level of 100 μL per well and incubated for 2 hours with agitation. Nonspecific antibodies not bound to the immobilized PNAFβ were eliminated by three washing steps with 200 μL of PBS 1x buffer, 0.05% Tween 20. The possible presence of specific antibodies was detected using 100 μL of mouse anti-Fc secondary antibody (Sigma #A0168) conjugated to HRP (horseradish peroxidase) diluted 1 / 10,000 in PBS, 0.1% BSA per well. After 1 hour of incubation at room temperature with agitation, followed by three washes with 200 μL of PBS 1× buffer, 0.05% Tween 20, development of HRP is carried out by a chromogenic assay at 450 nm after incubation of its TMB substrate (3,3′,5,5′-tetramethylbenzidine, Sigma No. T0440) for 20 minutes with agitation at room temperature. The blocking solution is then removed by aspiration, and the plates are stored at 4° C. for future use.

[0099] To ensure that the antibodies detected by the ELISA test were actually directed against the PNAFβ protein and not against the GST tag or biotin, the same punctures were preincubated with an excess of another orthogonal protein tagged with GST or biotin, followed by ELISA. Thus, the anti-tag antibody binds to the tagged orthogonal protein and therefore not to the PNAFβ protein immobilized at the bottom of the well, resulting in no or reduced HRP signal.

[0100] Fusion & Cloning Mice with the best anti-PNAFβ antibody titers (i.e., high optical density at 450 nm) and the least significant decrease in signal in the anti-TAG control are selected for the next step, lymphocyte hybridization, also called fusion. Mouse spleens are removed to isolate a mixture of lymphocytes and plasma cells. This multicellular sample is fused in vitro with a myeloma cell line in the presence of a polyethylene glycol (PEG)-type cell fusion catalyst. A mutant myeloma cell line lacking the enzyme HGPRT (hypoxanthine guanosine phosphoribosyltransferase) is used to allow the selection of hybrid cells, called hybridomas. These cells are cultured in a medium containing hypoxanthine, aminopterin (methotrexate), and thiamine (HAT medium), allowing the elimination of unfused myeloma cells and thus the selection of the desired hybridomas. Unfused spleen cells, on the other hand, die because they cannot proliferate in vitro. Therefore, only hybridomas survive this selection pressure in vitro.

[0101] These hybridomas are cultured in culture plates. The supernatants of these hybridomas are tested to evaluate their ability to produce anti-PNAFβ antibodies. For this purpose, ELISA tests are carried out as described above. The minimum threshold used to select clones is 4 times that of non-specific ones. To obtain stable hybridoma clones, the best hybridomas are cloned using limiting dilution steps.

[0102] The selected clones are cultured to form a hybridoma bank, tested for cell viability, and stored in liquid nitrogen. At this stage, the antibodies produced by the clones can be easily sequenced by methods well described in the prior art, for example, so that the antibodies can be produced in production cell lines. Alternatively, the antibodies are produced as described below.

[0103] Generation of anti-PNAFβ antibodies To allow for the production of large amounts of antibody in the ascites fluid, clones of the hybridoma of interest are put back into culture and the cell inoculum is then injected (intraperitoneal injection, IP) into BALB / c mice.

[0104] After characterization of the ascites contents by various techniques aimed at quantifying and qualifying the antibody content, the antibody is then purified by affinity chromatography on a column containing a Protein A-grafted resin, optionally followed by precipitation with salt. After washing the column to remove components separate from the antibody, the antibody content is eluted by shock with a glycine buffer at acidic pH. After pH neutralization and dialysis against a buffer at neutral pH, the anti-PNAFβ antibody is ready for storage at 4°C or frozen and for further use / characterization (isotyping, assays, functional tests).

[0105] Selection of antibody pairs capable of specifically binding to PNAFβ (ELISA method) To select pairs of antibodies that preferentially recognize PNAFβ over PAFβ, an ELISA-type test is performed. For this purpose, one of the antibodies to be tested is biotinylated using the Lightning-Link Rapid Biotin Type A Kit (Expedeon, reference SKU 370-0005) according to the supplier's recommendations. The second antibody of the pair to be tested, pre-diluted in PBS buffer to a concentration between 1 and 20 μg / mL, is adsorbed onto a 96-well plate in a "high-binding" ELISA format. For this purpose, 100 μL of antibody is added to each well, which is then incubated for 20 hours at 4°C, followed by three washes with PBS 1x buffer, 0.05% Tween 20. After removing the wash solution, each well is then incubated overnight at 4°C with 200 μL of a blocking solution composed of PBS, 5% BSA. This blocking solution is then removed by aspiration, and the plate is stored at 4°C for future use.

[0106] Serial dilutions of 1- to 1 / 100-fold dilutions of samples containing the same initial concentration of PNAFβ or PAFβ are added at a level of 100 μL per well and incubated for 2 hours at room temperature with agitation. PNAFβ or PAFβ not bound to the antibody adsorbed on the plate is removed by three washing steps with PBS 1x buffer, 0.05% Tween 20. Biotinylated antibodies pre-diluted in PBS buffer to concentrations between 10 and 200 ng / mL are added at a level of 100 μL per well and incubated for 2 hours at room temperature with agitation. Biotinylated antibodies not bound to PNAFβ or PAFβ are removed by three washing steps with PBS 1x buffer, 0.05% Tween 20. Detection of bound antibodies is performed using streptavidin-HRP (R&D Systems, reference DY998) diluted 1 / 10 in PBS, 0.1% BSA. After 30 minutes of incubation at room temperature with agitation, followed by three washes with PBS 1x buffer, 0.05% Tween 20, the optical density at 450 nm (OD450nm) is measured, followed by development of HRP by incubation with its TMB substrate (3,3',5,5'-tetramethylbenzidine, Sigma no. T0440) for 20 minutes at room temperature with agitation.

[0107] In the first step, a reference dilution of PNAFβ or PAFβ samples is determined by analyzing the OD450nm measured using various dilutions of PNAFβ. As shown in Figure 2, the reference dilution is the one that gives 80% of the maximum OD450nm.

[0108] In the second step, the OD450nm obtained using a reference dilution of a PNAFβ sample is compared with the OD450nm measured using the same dilution of a PAFβ sample. As shown in Figure 3, a pair of antibodies capable of specifically binding to PNAFβ results in a 50% lower OD450nm for the PAFβ sample compared to the OD450nm measured for the PNAFβ sample.

[0109] Selection of antibody pairs capable of specifically binding to PNAFβ (FRET method) A FRET experiment was set up to select a pair of antibodies that preferentially recognize PNAFβ over PAFβ. This experiment was based on Cisbio Bioassays HTRF® technology. The principle of this technique is based on fluorescence energy transfer between a donor molecule, terbium cryptate (donor), and a fluorescent energy acceptor molecule, d2 (acceptor). As illustrated in Figure 4, these two fluorescent molecules were covalently grafted onto the antibody, and an immunoassay was performed. For this purpose, one of the antibodies to be tested was labeled with the donor Lumi4 terbium using a Terbium Cryptate Labeling Kit (Cisbio Bioassays, reference 62TBSPEA) according to the manufacturer's recommendations. Before use, the donor-labeled antibody was diluted to a concentration of 0.5 nM in 20 mM Hepes buffer, pH 7.4, 0.1% BSA. The second antibody of the pair to be tested is labeled with acceptor d2 using a d2 labeling kit (Cisbio Bioassays reference 62D2DPEA) according to the supplier's recommendations. Before use, the donor-labeled antibody is diluted to a concentration of 5 nM in 20 mM Hepes buffer pH = 7.4, 0.1% BSA. Serial dilutions of 1 to 1 / 100-fold dilutions of samples containing the same initial concentration of PNAFβ or PAFβ are distributed into a 384-well microplate at a level of 16 μL / well. Then, 2 μL of a 0.5 nM solution of the donor-labeled antibody and 2 μL of a 5 nM solution of the acceptor-labeled antibody are added to each well. The microplate is incubated at room temperature for 20 hours. Detection of the FRET signal in the various plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0110] In the first step, a reference dilution of PNAFβ or PAFβ samples is determined by analyzing the HTRF signal measured using various dilutions of PNAFβ. As shown in Figure 5, the reference dilution is the one that yields 80% of the maximum HTRF signal before the saturation plateau of the immunoassay.

[0111] In the second step, the HTRF signal obtained using a reference dilution of a PNAFβ sample is compared to the HTRF signal measured using the same dilution of a PAFβ sample. As illustrated in Figure 6, a pair of antibodies capable of specifically binding to PNAFβ results in a 50% lower HTRF signal in the PAFβ sample compared to the HTRF signal measured in the PNAFβ sample.

[0112] Example 2 A method (FRET method) that allows identification of antibody pairs capable of specifically binding to TDP-43 NAFβ An alternative method for obtaining samples containing TDP-43 AFβ or TDP-43 NAFβ involves culturing HeLa cells and treating them with or without staurosporine for at least 6 hours. Analysis of cell lysates by SDS-PAGE and Western blot showed that untreated HeLa cell lysates contained TDP-43 NAFβ, whereas staurosporine-treated HeLa lysates essentially contained TDP-43 AFβ

[12] .

[0113] The method is based on the FRET technology described in Example 1 (HTRF® technology from Cisbio Bioassays).

[0114] Preparation of antibodies to be tested Five antibodies directed against TDP-43 were labeled with donors and acceptors, respectively. These were performed using labeling kits sold by Cisbio Bioassays (commercial references 62EUSUEA and 62D2DPEA). The resulting labeling ratios (number of fluorescent molecules per antibody) were consistent with expectations. The donor labeling ratios ranged from 5.9 to 7.9. The acceptor labeling ratios ranged from 2.3 to 3.3.

[0115] The table below shows the characteristics of the antibodies tested.

[0116] [Table 1]

[0117] To be tested, all antibodies were diluted in buffer to obtain respective concentrations of 3 nM for donor-labeled antibodies and 30 nM for acceptor-labeled ones.

[0118] Preparation of TDP-43 NAFβ (monomer) sample Flask (175cm 2 HeLa cells were seeded at 5 million cells in complete culture medium (MEM alpha medium + 2 mM Hepes + 10% complement-depleted fetal bovine serum + 1% antibiotics, penicillin 5000 U / ml, and streptomycin 5000 μg / ml) at 4°C (Table 1). After 78 hours, the culture medium was aspirated. Cells were then lysed using cell lysis buffer. The resulting lysate containing TDP-43 NAFβ (hereafter referred to as the "monomer sample") was frozen at -80°C for further use. The sample was examined by Western blot as recommended in

[12] to ensure that it essentially contained non-aggregated TDP43 (TDP-43 NAFβ).

[0119] Preparation of TDP-43 AFβ (aggregates) samples Flask (175cm 2HeLa cells were seeded at 5 million cells in complete culture medium (MEM alpha medium + 2 mM Hepes + 10% complement-depleted fetal bovine serum + 1% antibiotics, penicillin 5000 U / ml, and streptomycin 5000 μg / ml) in a 100-well plate. After 72 hours, the culture medium was aspirated. A 1 μM solution of staurosporine in complete medium was added to the cultured cells for 6 hours. Treatment of the cells with staurosporine aggregates TDP-43, allowing TDP-43 AFβ to be obtained. The culture medium was then aspirated, followed by the addition of cell lysis buffer. The resulting lysate containing TDP-43 AFβ (hereinafter referred to as the "aggregate sample") was frozen at -80°C for further use. This sample was examined by Western blot as recommended in

[12] to ensure that it essentially contained aggregated TDP43 (TDP-43 AFβ).

[0120] Screening antibody pairs in monomers or aggregates On the day of testing, monomer and aggregate samples were thawed and then distributed into 384-well microplates (Greiner reference 784075).

[0121] The following reagents were added to the microplate in the following order: 16 μL of monomer or aggregate sample, -2 μL of donor antibody, -2 μL of acceptor antibody.

[0122] The plates were then incubated overnight at room temperature.

[0123] Detection of FRET signals in the various plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module. For all tested antibody pairs, the signals obtained in FRET for the monomer and aggregate samples were compared by calculating the ratio of the FRET signals (monomer / aggregate), as shown in Figure 7 using the pair Ac1-donor / Ac4-acceptor.

[0124] The FRET signal ratio (monomer / aggregate) was calculated for all antibody pairs tested. The results are summarized in Table 2 below. All antibody pairs with a ratio (monomer / aggregate) greater than 2 are considered selective for TDP-43 NAFβ over TDP-43 AFβ.

[0125] [Table 2]

[0126] Seven antibody pairs allowed us to distinguish TDP-43 NAFβ from TDP-43 AFβ because they had a monomer / aggregate ratio greater than 2. They are listed in Table 3.

[0127] [Table 3]

[0128] Example 3 A method for identifying antibody pairs capable of specifically binding to the beta 1-40 amyloid peptide NAFβ (FRET method) The method is based on the FRET technology (HTRF® technology from Cisbio Bioassays) detailed in Example 1.

[0129] Tested antibody pairs The donor- and acceptor-labeled antibodies directed against the beta 1-40 amyloid peptide were those contained in the amyloid beta 1-40 HTRF kit sold by Cisbio Bioassays (reference 62B40PEG) and were diluted in the reference diluent 62RB3FDG as recommended by the amyloid beta 1-40 HTRF kit manual.

[0130] Preparation of beta 1-40 amyloid peptide NAFβ (monomer) Lyophilized human beta 1-40 amyloid peptide (ERI275BAS, The ERI Amyloid Laboratory, LLC, Oxford) was resuspended according to the supplier's recommendations and then diluted to a concentration of 30 μM with 10 mM sodium phosphate pH 7.4 buffer. The solution containing beta 1-40 amyloid peptide NAFβ (hereinafter referred to as the "monomer sample") was then frozen at -80°C. A thioflavin T test was performed on this solution, which showed that it contained more than 90% beta 1-40 amyloid peptide monomer.

[0131] Preparation of beta 1-40 amyloid peptide AFβ (aggregates) Lyophilized human beta 1-40 amyloid peptide (ERI275BAS, The ERI Amyloid Laboratory, LLC, Oxford) was resuspended according to the supplier's recommendations and then diluted to a concentration of 30 μM with 10 mM sodium phosphate pH 7.4 buffer. This solution was then incubated at 25°C for 495 hours, allowing the beta 1-40 amyloid peptide to aggregate and obtain beta 1-40 amyloid peptide AFβ. The solution containing beta 1-40 amyloid peptide AFβ (hereinafter referred to as the "aggregate sample") was then frozen at -80°C. A thioflavin T test was performed on this solution, showing that it contained more than 90% beta 1-40 amyloid peptide aggregates.

[0132] Testing antibody pairs as monomers or aggregates On the day of testing, monomer and aggregate samples were thawed and then diluted to a concentration of 20.3 ng / mL in 10 mM sodium phosphate pH 7.4 buffer before being distributed into 384-well microplates (Greiner reference 784075).

[0133] The following reagents were added to the microplate in the following order: - 5 μL of monomer or aggregate sample - 5 μL of diluent (reference 62DL1DDD, Cisbio Bioassays) -5 μL of donor antibody -5 μL of acceptor antibody

[0134] The plates were then incubated overnight at a temperature comprised between 2°C and 8°C.

[0135] Detection of FRET signals in the various plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module. As shown in Figure 8, the signals obtained in the FRET of the monomer and aggregate samples were compared by calculating the ratio of the FRET signals (monomer / aggregate).

[0136] The FRET (monomer / aggregate) signal ratio of the antibody pair is greater than 2 (a value of 3.1), indicating that this antibody pair distinguishes beta 1-40 amyloid peptide NAFβ from beta amyloid peptide 1-40 AFβ, i.e., that this antibody pair is specific for beta amyloid peptide 1-40 NAFβ.

[0137] Example 4 A method for identifying a pair of antibodies capable of specifically binding to beta-amyloid peptide 1-42 NAFβ (FRET method) The method is based on the FRET technology (HTRF® technology from Cisbio Bioassays) detailed in Example 1.

[0138] Tested antibody pairs Two antibodies directed against beta-amyloid peptide 1-42, labeled with donor and acceptor, respectively, were diluted to concentrations of 3 nM (donor) and 30 nM (acceptor), respectively.

[0139] Preparation of beta 1-42 amyloid peptide NAFβ (monomer) Lyophilized human beta amyloid peptide 1-42 (The ERI Amyloid Laboratory, LLC, Oxford) was resuspended according to the supplier's recommendations and then diluted to a concentration of 30 μM with 10 mM sodium phosphate pH 7.4 buffer. The solution containing beta amyloid peptide 1-42 NAFβ (hereinafter referred to as the "monomer sample") was then frozen at -80°C. A thioflavin T test was performed on this solution, which showed that it contained more than 90% beta amyloid peptide 1-42 monomer.

[0140] Preparation of beta amyloid peptide 1-42 AFβ (aggregate) Lyophilized human beta amyloid peptide 1-42 (ERI275BAS, The ERI Amyloid Laboratory, LLC, Oxford) was resuspended according to the supplier's recommendations and then diluted to a concentration of 30 μM with 10 mM sodium phosphate pH 7.4 buffer. This solution was then incubated at 25°C for 188 hours. The solution containing beta amyloid peptide 1-42 AFβ (hereinafter referred to as the "aggregate sample") was then frozen at -80°C. A thioflavin T test was performed on this solution, which showed that it contained more than 90% beta amyloid peptide 1-42 aggregates.

[0141] Testing antibody pairs as monomers or aggregates On the day of testing, monomer and aggregate samples were thawed and then diluted to a concentration of 2.4 ng / mL in 10 mM sodium phosphate pH 7.4 buffer before being distributed into 384-well microplates (Greiner reference 784075).

[0142] The following reagents were added to the microplate in the following order: -16 μL of monomer or aggregate sample -2 μL of donor antibody -2 μL of acceptor antibody.

[0143] The plates were incubated overnight at a temperature comprised between 2°C and 8°C.

[0144] Detection of FRET signals in the various plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module. As shown in Figure 9, the signals obtained in the FRET of the monomer and aggregate samples were compared by calculating the ratio of the FRET signals (monomer / aggregate).

[0145] The FRET signal (monomer / aggregate) ratio of the studied antibody pair is greater than 2 (value of 4.5), indicating that this antibody pair distinguishes beta 1-42 amyloid NAFβ from beta amyloid 1-42 AFβ, i.e., that this antibody pair is specific for the beta amyloid peptide 1-42 NAFβ.

[0146] Example 5 Examination of the effect of hexafluoroisopropanol (HFIP) on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ HFIP was used pure (100%) or diluted with lysis buffer to obtain 20%, 10%, and 2% solutions.

[0147] The following reagents were dispensed into a 384-well plate in the following order: 1) 8 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of various solutions of 100%, 20%, 10% and 2% HFIP or supplemented lysis buffer. 3) Addition of FRET detection reagent: 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0148] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0149] Figure 10 shows the signals obtained using various tested concentrations of HFIP. At concentrations higher than 2%, HFIP reduces the detection signal of TDP-43 NAFβ by more than 75%. Therefore, its possible effect on aggregation is evaluated in this format using a concentration of 2%.

[0150] Example 6 Testing HFIP as a disaggregating agent for TDP-43 AFβ HFIP was diluted with lysis buffer to give a 2% solution.

[0151] The following reagents were dispensed into a 384-well plate in the following order: 1) 8 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. 2) 8 μL of 2% HFIP solution or lysis buffer. 3) Addition of FRET detection reagent: 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0152] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0153] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0154] Signal ratio = (sample signal treated with 2% HFIP) / (sample signal treated with lysis buffer).

[0155] Figure 11 shows the results obtained. The signal ratio was less than 1 (0.89), indicating that 2% HFIP treatment did not increase the detection of PNAFβ in samples containing TDP-43 AFβ. It can be concluded that treatment with 2% HFIP does not allow TDP-43 AFβ to be disaggregated even partially.

[0156] Example 7 Examination of the effect of urea on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ Urea was diluted with lysis buffer to give 7M, 3.5M, 1.75M and 0.88M solutions.

[0157] The following reagents were dispensed into a 384-well plate in the following order: 1) 8 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of various 7M, 3.5M, 1.75M and 0.88M urea solutions or lysis buffer. 3) Addition of FRET detection reagent: 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0158] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0159] Figure 12 shows the signals obtained using various test concentrations of urea. For concentrations above 3.5M, urea reduces the detection signal of TDP-43 NAFβ by more than 75%. Therefore, its possible effect on aggregation is evaluated in this format using concentrations below 3.5M.

[0160] Example 8 Testing urea as a disruptant of TDP-43 AFβ Dilutions were made with lysis buffer supplemented with urea to give 3.5M, 1.75M and 0.88M solutions.

[0161] The following reagents were dispensed into a 384-well plate in the following order: 1) 8 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. 2) 8 μL of urea solutions or lysis buffer at various concentrations (3.5 M, 1.75 M, and 0.88 M). 3) Addition of FRET detection reagent: - 2 μL of donor antibody Ac1, prepared as described in Example 2. - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0162] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0163] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0164] Signal ratio = (sample signal treated with 3.5 M urea) / (sample signal treated with supplemented lysis buffer).

[0165] Figure 13 shows the results obtained. The signal ratio was 1 or less for all tested concentrations of urea, indicating that these treatments did not increase the detection of TDP-43 PNAFβ in aggregate samples. It can be concluded that treatment with urea concentrations of 3.5 M or less did not even partially disaggregate TDP-43 AFβ.

[0166] Example 9 Examination of the effect of guanidinium chloride on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ Guanidinium chloride was diluted with supplemented lysis buffer to give 6M, 3M and 1.5M solutions.

[0167] The following reagents were dispensed into a 384-well plate in the following order: 1) 8 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of various guanidinium chloride solutions of 6 M, 3 M, and 1.5 M or supplemented lysis buffer. 3) Addition of FRET detection reagent: 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0168] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0169] Figure 14 shows the signals obtained using various test concentrations of guanidinium chloride. Regardless of its concentration, guanidinium chloride reduces the detection signal of TDP-43 NAFβ by more than 75%. Therefore, this compound interferes with the detection of TDP-43 NAFβ, and its possible effect on aggregation cannot be evaluated in this format.

[0170] Example 10 Examination of the effects of formic acid (FA) and trifluoroacetic acid (TFA) on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ FA and TFA were diluted with supplemented lysis buffer to give 20%, 10% and 2% solutions.

[0171] The following reagents were dispensed into a 384-well plate in the following order: 1) 8 μL of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of various solutions of 20%, 10% and 2% FA or TFA or supplemented lysis buffer. 3) Addition of FRET detection reagent: 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0172] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0173] Figure 15 shows the signals obtained using various test concentrations of FA or TFA. Regardless of their concentration, these reagents reduce the detection signal of TDP-43 NAFβ by more than 75%. Therefore, their potential effect on aggregation cannot be evaluated in this format because they interfere with the detection of TDP-43 NAFβ.

[0174] Example 11 Examination of the effect of formic acid (FA) followed by neutralization with NaOH on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ FA was diluted with supplemented lysis buffer to obtain a 20% solution.

[0175] NaOH was diluted with 450 mM HEPES buffer to give a 5N solution.

[0176] The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% FA solution or supplemented lysis buffer. The mixture was incubated at room temperature for 15 minutes. The pH measured at this step was equal to 2.5. 3) 9 μL of 5N NaOH solution or supplemented lysis buffer, after which the measured pH is equal to 7.6.

[0177] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0178] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0179] In Figure 16, the PNAFβ detection signal obtained using FA followed by NaOH treatment is compared with that obtained in the absence of treatment. The treatment causes almost complete disappearance of the TDP-43 NAFβ detection signal. Therefore, its possible effect on TDP-43 AFβ disaggregation cannot be evaluated.

[0180] Example 12 Examination of the effect of trifluoroacetic acid (TFA) followed by neutralization with NaOH on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ TFA was diluted with supplemented lysis buffer to give a 20% solution.

[0181] NaOH was diluted with 450 mM HEPES buffer to give a 5N solution.

[0182] The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% TFA solution or supplemented lysis buffer. The mixture was incubated at room temperature for 15 minutes. The pH measured at this step was equal to 0.6. 3) 4.5 μL of 5N NaOH solution or supplemented lysis buffer. The pH measured after this addition is equal to 7.5.

[0183] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0184] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0185] In Figure 17, the PNAFβ detection signal obtained with TFA followed by NaOH treatment is compared to that obtained in the absence of treatment. Even though this treatment significantly affected the TDP-43 PNAFβ detection signal (-62%), the remaining signal allowed us to test it for TDP-43 PNAFβ disaggregation.

[0186] Example 13 Examining the effect of trifluoroacetic acid (TFA) followed by neutralization with NaOH as a disruptor of TDP-43 AFβ

[0187] TFA was diluted with supplemented lysis buffer to give a 20% solution.

[0188] NaOH was diluted with 450 mM HEPES buffer to give a 5N solution.

[0189] The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μl of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% TFA solution or TFA / NaOH mixture (obtained by mixing 8 volumes of 20% TFA solution with 4.5 volumes of 5N NaOH solution). The mixture was incubated at room temperature for 15 minutes. 3) 4.5 μL of 5N NaOH solution or TFA / NaOH mixture. The pH measured after this addition is equal to 7.5.

[0190] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0191] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0192] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0193] Signal ratio = (sample signal treated with 20% TFA followed by 5N NaOH) / (sample signal treated with TFA / NaOH mixture).

[0194] Figure 18 shows the results obtained. The signal ratio was less than 1 (0.56), indicating that the treatment did not increase the detection of TDP-43 NAFβ in the aggregate sample. It can be concluded that treatment with 20% TFA followed by neutralization with NaOH does not disaggregate TDP-43 AFβ, even partially.

[0195] Example 14 Examination of the effect of formic acid (FA) followed by neutralization with NH4OH on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ FA was diluted with supplemented lysis buffer to obtain a 20% solution.

[0196] NH4OH was diluted with 450 mM HEPES buffer to obtain a 5N solution.

[0197] The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% FA solution or supplemented lysis buffer. The mixture was incubated at room temperature for 15 minutes. The pH measured at this step was equal to 2.5. 3) 12 μL of a 5N NH4OH solution. The pH measured after this addition is equal to 7.2.

[0198] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0199] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0200] In Figure 19, the TDP-43 NAFβ detection signal obtained with FA followed by NH4OH treatment is compared to that obtained in the absence of treatment. Even though this treatment significantly affected the TDP-43 NAFβ detection signal (-68%), the remaining signal allowed us to test it for TDP-43 AFβ disaggregation.

[0201] Example 15 Examining the effect of formic acid (FA) followed by neutralization with NH4OH as a disruptor of TDP-43 AFβ FA was diluted with supplemented lysis buffer to obtain a 20% solution.

[0202] NH4OH was diluted with 450 mM HEPES buffer to obtain a 5N solution.

[0203] The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% FA solution or FA / NH4OH mixture (obtained by mixing 8 volumes of 20% TFA solution with 12 volumes of 5N NH4OH solution). The mixture was incubated at room temperature for 15 minutes. 3) 12 μL of 5N NH4OH solution or FA / NH4OH mixture. The pH measured after this addition is equal to 7.2.

[0204] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0205] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0206] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0207] Signal ratio = (sample signal treated with 20% FA followed by 5N NH4OH) / (sample signal treated with FA / NH4OH mixture).

[0208] Figure 20 shows the results obtained. The signal ratio was less than 1 (0.78), indicating that the treatment did not increase the detection of TDP-43 NAFβ in the aggregate sample. It can be concluded that treatment with 20% FA followed by neutralization with NH4OH does not disaggregate TDP-43 AFβ, even partially.

[0209] Example 16 Examination of the effect of trifluoroacetic acid (TFA) followed by neutralization with NH4OH on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ TFA was diluted with supplemented lysis buffer to give a 20% solution.

[0210] NH4OH was diluted with 450 mM HEPES buffer to obtain a 5N solution.

[0211] The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% TFA solution or supplemented lysis buffer. The mixture was incubated at room temperature for 15 minutes. The pH measured at this step was equal to 0.6. 3) 7 μL of a 5N NH4OH solution. The pH measured after this addition is equal to 7.5.

[0212] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0213] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0214] In Figure 21, the PNAFβ detection signal obtained with TFA followed by NH4OH treatment is compared to that obtained in the absence of treatment. Even though this treatment significantly affected the TDP-43 PNAFβ detection signal (-72%), the remaining signal allowed us to test it for TDP-43 PNAFβ disaggregation.

[0215] Example 17 Examining the effect of trifluoroacetic acid (TFA) followed by neutralization with NH4OH as a disruptor of TDP-43 AFβ TFA was diluted with supplemented lysis buffer to give a 20% solution.

[0216] NH4OH was diluted with 450 mM HEPES buffer to obtain a 5N solution. The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. 2) 8 μL of 20% TFA solution or TFA / NH4OH mixture (obtained by mixing 8 volumes of 20% TFA solution with 7 volumes of 5N NH4OH solution). The mixture was incubated at room temperature for 15 minutes. 3) 7 μl of a 5N NH4OH solution or a TFA / NH4OH mixture. The pH measured after this addition is equal to 7.5.

[0217] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0218] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0219] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0220] Signal ratio = (sample signal treated with 20% TFA followed by 5N NH4OH) / (sample signal treated with TFA / NH4OH mixture).

[0221] Figure 22 shows the results obtained. The signal ratio was less than 1 (0.42), indicating that the treatment did not increase the detection of TDP-43 NAFβ in the aggregate sample. It can be concluded that treatment with 20% TFA followed by neutralization with NH4OH does not disaggregate TDP-43 AFβ, even partially.

[0222] Example 18 Effect of NaOH solutions exhibiting pH values ​​comprised between 8.2 and 13.3, followed by neutralization with HCl, on the method using the TDP-43 NAFβ detection reagent Tested NaOH solutions

[0223] [Table 4]

[0224] Tested HCl solutions

[0225] [Table 5]

[0226] Tested NaOH / HCl mixtures (obtained by mixing equal volumes of NaOH and HCl solutions)

[0227] [Table 6]

[0228] The following reagents were dispensed into a 96-well plate: - 60 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. -10 μL of various NaOH solutions (A, B, C, D, E or F) or buffer. The mixture was incubated at room temperature for 15 minutes. - 10 μL of various HCl solutions (A, B, C, D, E or F) or buffer.

[0229] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0230] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0231] Figure 23 shows the results obtained using various treatment modalities. Treatment with NaOH solution resulting in a pH of 13.3, followed by neutralization with HCl, does not allow detection of TDP-43 NAFβ. The disintegrating power of all other solutions could be tested on TDP-43 AFβ.

[0232] Example 19 Determination of the minimum and maximum pH to disaggregate TDP-43 AFβ using NaOH Tested NaOH solutions

[0233] [Table 7]

[0234] Tested HCl solutions

[0235] [Table 8]

[0236] Tested NaOH / HCl mixtures (obtained by mixing equal volumes of NaOH and HCl solutions)

[0237] [Table 9]

[0238] The following reagents were dispensed into a 96-well plate: - 60 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. - 10 μL of various NaOH solutions (A, B, C, D or E) or the corresponding NaOH / HCl mixtures (A, B, C, D or E). The mixtures were incubated at room temperature for 15 minutes. -10 μL of various HCl solutions (A, B, C, D, E) or the corresponding NaOH / HCl mixtures (A, B, C, D, E).

[0239] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0240] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0241] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0242] Ratio of signals = (Sample signal treated with NaOH then HCl) / (Sample signal treated with NaOH / HCl mixture).

[0243] Figure 24 shows the results obtained as a function of pH induced by the various NaOH solutions tested. Detection of TDP-43 NAFβ is possible when the pH ranges from 8.5 to 13.2 during the disaggregation step. However, the pH that allows for the optimal amplitude for detecting TDP-43 NAFβ is approximately pH 12.8.

[0244] Example 20 Determination of the time required to disaggregate TDP-43 AFβ at a pH of 12.8 The following reagents were dispensed into a 96-well plate in the following order: 1) 60 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2 2) 10 μL of 1.2 N NaOH solution (to bring the pH of the sample to 12.8) or NaOH / HCl mixture (obtained by mixing equal volumes of 1.2 N NaOH solution and 1 N HCl solution). The mixture was incubated at room temperature for 30 seconds to 1 hour depending on the well. 3) 10 μL of 1 N HCl solution (pH of sample brought to 7.5) in wells treated with 1.2 N NaOH or 10 μL of NaOH / HCl mixture in wells treated with NaOH / HCl mixture.

[0245] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0246] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0247] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0248] Ratio of signals = (Sample signal treated with 1.2N NaOH followed by 1N HCl) / (Sample signal treated with NaOH / HCl mixture).

[0249] Figure 25 shows the results obtained as a function of contact time with 1.2 N NaOH. The results show that 1.2 N NaOH treatment allowed at least partial disaggregation of TDP-43 AFβ, independent of contact time (signal ratios were always greater than 1). However, the best disaggregation was obtained for contact times ranging from 5 to 30 minutes.

[0250] Example 21 Determination of minimum and maximum pH when measuring detection of TDP-43 NAFβ Tested NaOH solutions

[0251] 1.2N NaOH solution (allows the pH of the sample to be brought to 12.8)

[0252] Tested HCl solutions

[0253] [Table 10]

[0254] Tested NaOH / HCl mixtures (obtained by mixing equal volumes of NaOH and HCl solutions)

[0255] [Table 11]

[0256] The following reagents were dispensed into a 96-well plate: - 60 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. - 10 μL of various 1.2 N NaOH solutions or the corresponding NaOH / HCl mixtures (A, B, C, D, E, F, G, H or I). The mixtures were incubated at room temperature for 15 minutes. - 10 μL of various HCl solutions (A, B, C, D, E, F, G, H or I) or the corresponding NaOH / HCl mixtures (A, B, C, D, E, F, G, H or I).

[0257] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0258] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0259] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0260] Signal ratio = (sample signal treated with 1.2N NaOH, then HCl) / (sample signal treated with NaOH / HCl mixture).

[0261] Figure 26 shows that after treatment at pH = 12.8, TDP-43 NAFβ can be detected if the pH is then returned to between pH = 6 and pH = 10.5. Detection is optimal when the pH is between 6 and 8.5.

[0262] Example 22 Measurement of the level of aggregation of beta-amyloid peptide 1-42 using NaOH as a disaggregating agent and HCl as a neutralizing agent The method described below is based on the HTRF technique (see Example 1 for principle).

[0263] 1.2N NaOH and 1N HCl solutions were prepared as described in previous examples.

[0264] Preparation of samples containing monomeric (1-42 NAFβ) or aggregated (1-42 AFβ) beta 1-42 amyloid peptide: Lyophilized human beta 1-42 amyloid peptide (ERI275BAS, The ERI Amyloid Laboratory, LLC, Oxford) was resuspended according to the supplier's recommendations and then diluted to a concentration of 30 μM (1-42 NAFβ) in 10 mM sodium phosphate pH 7.4 buffer. Identical solutions of beta 1-42 amyloid peptide were incubated at 25°C for 188 hours to obtain 1-42 AFβ. Two samples were frozen at -80°C before future use. The level of aggregation in both samples was examined by the thioflavin T method before use.

[0265] On the day of the test, samples 1-42 NAFβ and 1-42 AFβ were thawed and then diluted to a concentration of 2.4 ng / mL with 10 mM sodium phosphate buffer pH 7.4, and then distributed into microplates.

[0266] The following reagents were dispensed into a 384-well plate in the following order: 1) 12 μL of 1-42 AFβ sample or 1-42 NAFβ sample. 2) 2 μL of 1.2 N NaOH solution or NaOH / HCl mixture (obtained by mixing equal volumes of 1.2 N NaOH solution and 1 N HCl solution). The mixture was incubated at room temperature for 15 minutes. 3) 2 μL of 1N HCl solution or NaOH / HCl mixture. 4) Addition of FRET detection reagent: - 2 μL of donor antibody prepared as described in Example 4. - 2 μL of acceptor antibody prepared as described in Example 4.

[0267] The plates were incubated overnight at a temperature comprised between 2°C and 8°C.

[0268] Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0269] The aggregation ratio is calculated from the HTRF signal obtained for the sample as follows:

[0270] Signal ratio = (sample signal treated with 1.2N NaOH followed by 1N HCl) / (sample signal treated with NaOH / HCl mixture).

[0271] Figure 27 shows the signal ratios obtained using samples 1-42 NAFβ and 1-42 AFβ. The signal ratio obtained with the 1-42 AFβ sample is significantly higher than that obtained with the 1-42 NAFβ sample. This result indicates that the method can measure the level of 1-42 amyloid peptide aggregation.

[0272] Example 23 Effect of treatment with NaOH, potassium hydroxide (KOH), or NH4OH, followed by neutralization with HCl, on the detection ability of a method using a pair of antibodies capable of specifically binding to TDP-43 NAFβ Preparation of NaOH, KOH, NH4OH, and HCl solutions for treating TDP43-AFβ lysates

[0273] [Table 12]

[0274] Tested HCl solutions

[0275] [Table 13]

[0276] Tested base / HCl mixtures (obtained by mixing equal volumes of NaOH and HCl solutions)

[0277] [Table 14]

[0278] The following reagents were dispensed into a 96-well plate: - 60 μL of a sample of TDP-43 NAFβ prepared according to the protocol described in Example 2. -10 μL of various base solutions (A, B, C, D or E) or the corresponding base / HCl mixtures (A, B, C, D or E). The mixtures were incubated at room temperature for 15 minutes. - 10 μL of various HCl solutions (A, B, C, D, E) or the corresponding base / HCl mixtures (A, B, C, D, E).

[0279] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0280] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0281] Figure 28 shows the TDP-NAFβ detection signals obtained using various treatments. Detection of TDP-43 NAFβ is possible regardless of the base used, provided that a neutralization step using HCl is performed, allowing a pH comprised between 7 and 8. Therefore, the disruptive effect of these bases on TDP-43 AFβ is tested.

[0282] Example 24 Effect of treatment with NaOH, potassium hydroxide (KOH), or NH4OH followed by neutralization with HCl on disaggregation of TDP-43 AFβ Preparation of NaOH, KOH, NH4OH, and HCl solutions for treating TDP43-AFβ lysates

[0283] [Table 15]

[0284] Tested HCl solutions

[0285] [Table 16]

[0286] Tested base / HCl mixtures (obtained by mixing equal volumes of NaOH and HCl solutions)

[0287] [Table 17]

[0288] The following reagents were dispensed into a 96-well plate: - 60 μL of a sample of TDP-43 AFβ prepared according to the protocol described in Example 2. -10 μL of various base solutions (A, B, C, D or E) or the corresponding base / HCl mixtures (A, B, C, D or E). The mixtures were incubated at room temperature for 15 minutes. - 10 μL of various HCl solutions (A, B, C, D, E) or the corresponding base / HCl mixtures (A, B, C, D, E).

[0289] A portion of the contents of the wells of the 96-well plate was transferred to a 384-well plate, after which FRET detection reagent was added using: -16 μL of the mixture from a 96-well plate 2 μL of donor antibody Ac1 prepared as described in Example 2 - 2 μL of acceptor antibody Ac2, prepared as described in Example 2.

[0290] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0291] The ratio of the resulting signals was calculated from the FRET signals obtained in the samples as follows:

[0292] Ratio of signals = (Sample signal treated with base then HCl) / (Sample signal treated with base / HCl mixture).

[0293] Figure 29 shows the signal ratios obtained using various treatments. Two NaOH treatment conditions (1.2N and 0.8N), which result in pH values ​​of 12.8 and 9.6, respectively, enable the detection of TDP43-NAFβ, thereby confirming the disaggregation effect on TDP-43 AFβ. Treatment with 1.2N KOH (pH = 12.5) allows weak detection of TDP43-NAFβ, indicating a weak disaggregation effect on TDP-43 AFβ. Two treatments using NH4OH (10N and 1.2N), which result in pH values ​​similar to those of the NaOH treatment, do not allow the detection of TDP43-NAFβ. This result indicates that NH4OH has no disaggregation effect on TDP-43 AFβ.

[0294] Example 25 Method for identifying pairs of antibodies capable of specifically binding to alpha-synuclein NAFβ (Alpha-Syn NAFβ) The method is based on the FRET technology (HTRF® technology from Cisbio Bioassays) detailed in Example 1.

[0295] Tested antibody pairs The pair of antibodies directed against alpha-synuclein, labeled with a donor and with an acceptor, respectively, was included in the HTRF Total-alpha-synuclein kit sold by Cisbio Bioassays (reference 6FNSYPEG). Each antibody was diluted in the kit diluent as recommended by the user manual.

[0296] Preparation of Alpha-Syn NAFβ and Alpha-Syn NAFβ samples Alpha-Syn NAFβ and Alpha-Syn AFβ were obtained from StressMarq (StressMarq Active Human Recombinant A53T Mutant Alpha-Synuclein Protein Monomer, Reference SPR-325 and Active Human Recombinant A53T Mutant Alpha-Synuclein Protein Preformed Fibril Type 1, Reference SPR-326) and diluted to 15.6 ng / mL in lysis buffer from the HTRF Total-A-Synuclein Kit.

[0297] Testing of antibody pairs with Alpha-Syn NAFβ and Alpha-Syn AFβ The following reagents were dispensed into a 384-well plate in the following order: 1) 12 μL of 15.6 ng / mL Alpha-Syn NAFβ or Alpha-Syn AFβ. 2) 2 μL of lysis buffer. The mixture was incubated at room temperature for 15 minutes. 3) 2 μL of lysis buffer. 4) 2 μL of donor antibody. 5) 2 μL of acceptor antibody.

[0298] Detection of the FRET signal in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0299] As shown in Figure 30, the signals obtained in FRET for Alpha-Syn NAFβ samples (monomer) and Alpha-Syn AFβ samples (aggregates) were compared by calculating the ratio of FRET signals (monomer / aggregates).

[0300] The ratio of FRET (monomer / aggregate) signals for the antibody pair is greater than 2 (value of 6.64), indicating that this antibody pair can specifically bind to Alpha-Syn NAFβ over Alpha-Syn AFβ.

[0301] Example 26 Effect of 1.2N NaOH solution followed by neutralization with 1N HCl on the detection ability of a method using a pair of antibodies capable of specifically binding to Alpha-Syn NAFβ Alpha-Syn NAFβ (StressMarq, active human recombinant A53T mutant alpha-synuclein protein monomer, reference SPR-326) was diluted to 15.6 ng / mL in the lysis buffer of the HTRF Total-Alpha-Synuclein Kit (Cisbio Bioassays, reference 6FNSYPEG). The donor and acceptor antibodies in the HTRF Total-A-Synuclein Kit were diluted as recommended by the supplier in the kit manual.

[0302] The following reagents were dispensed into a 384-well plate in the following order: 1) 12 μL of 15.6 ng / mL Alpha-Syn NAFβ. 2) 2 μL of 1.2 N NaOH solution (to bring the pH of the sample to 12.8) or NaOH / HCl mixture (obtained by mixing the same volumes of 1.2 N NaOH solution and 1 N HCl solution). The mixture was incubated at room temperature for 15 minutes. 3) 2 μL of 1 N HCl solution (pH of sample brought to 7.5) in wells treated with 1.2 N NaOH or 2 μL of NaOH / HCl mixture in wells treated with NaOH / HCl mixture. 4) 2 μL of donor antibody prepared as described in Example 25 5) 2 μL of acceptor antibody prepared as described in Example 25

[0303] The plates were incubated overnight at room temperature. Detection of HTRF signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0304] Figure 31 shows the results obtained. They show that treatment with 1.2 N NaOH followed by neutralization with 1 N HCl has little effect on the detection of Alpha-Syn NAFβ by the antibody. Thus, the effect of this treatment on the isolation of Alpha-Syn AFβ can be assessed.

[0305] Example 27 Determination of the level of aggregation of alpha-synuclein using NaOH as a disintegrant and HCl as a neutralizer The method is based on the FRET technology (HTRF® technology from Cisbio Bioassays) detailed in Example 1.

[0306] Tested antibody pairs The donor- and acceptor-labeled antibodies directed against alpha-synuclein were those contained in the HTRF Total-alpha-synuclein kit sold by Cisbio Bioassays (reference 6FNSYPEG) and were diluted in the kit diluent as recommended by the user manual.

[0307] Preparation of Alpha-Syn NAFβ and Alpha-Syn NAFβ samples Alpha-Syn NAFβ and Alpha-Syn AFβ were obtained from StressMarq (StressMarq Active Human Recombinant A53T Mutant Alpha-Synuclein Protein Monomer, reference SPR-325 and Active Human Recombinant A53T Mutant Alpha-Synuclein Protein Preformed Fibril Type 1, reference SPR-326) and diluted to 15.6 ng / mL in the lysis buffer of the HTRF Total-Alpha-Synuclein Kit.

[0308] Testing of antibody pairs with Alpha-Syn NAFβ and Alpha-Syn AFβ The following reagents were dispensed into a 384-well plate in the following order: 1) 12 μL of 15.6 ng / mL Alpha-Syn NAFβ or Alpha-Syn AFβ. 2) 2 μL of 1.2 N NaOH solution (to bring the pH of the sample to 12.8) or NaOH / HCl mixture (obtained by mixing the same volumes of 1.2 N NaOH solution and 1 N HCl solution). The mixture was incubated at room temperature for 15 minutes. 3) 2 μL of 1 N HCl solution (pH of sample brought to 7.5) in wells treated with 1.2 N NaOH or 2 μL of NaOH / HCl mixture in wells treated with NaOH / HCl mixture. 4) 2 μL of donor antibody. 5) 2 μL of acceptor antibody.

[0309] Detection of FRET signals in the different plates was performed with a PHERAstar FS Lamp instrument (BMG Labtech) using the HTRF detection module.

[0310] Figure 32 shows the signal ratios obtained using the Alpha-Syn NAFβ and Alpha-Syn AFβ samples. The signal ratio obtained with the Alpha-Syn AFβ sample is significantly higher than that obtained with the Alpha-Syn NAFβ sample. This result demonstrates that the method according to the present invention makes it possible to measure the level of alpha-synuclein aggregation.

[0311] References [1] Harrison et al., RNA-binding proteins with prion-like domains in health and disease (2017) Biochem J.;474(8):1417-1438. doi:10.1042 / BCJ20160499 [2] Chang et al., Detection and quantification of TAU aggregation using a membrane filter assay, Analytical Biochemistry 373 (2008) pp. 330-336 [3] Howlett et al., Inhibition of fibril formation in b-amyloid peptide by a novel series of benzofurans, Biochem. J. (1999) 340, pp. 283-289 [4] Linghagen-Persson et al., Amyloid-b Oligomer Specificity Mediated by the IgM Isotype - Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies, PLoS ONE, November 2010 | Volume 5 | Issue 11 | e13928 [5]Englund et al., Sensitive ELISA detection of amyloid-b protofibrils in biological samples, Journal of Neurochemistry, 2007, 103, pp. 334 - 345 [6]Van Helmond et al., Higher Soluble Amyloid b Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer’s Disease, Brain Pathology ISSN 1015 - 6305, doi:10.1111 / j.1750 - 3639.2010.00374.x [7]Selkoe et al., Isolation of Low - Molecular - Weight Proteins from Amyloid Plate Fibers in Alzheimer’s Disease, Journal of Neurochemistry, (1986) [8]Janssen et al., Signal loss due to oligomerization in ELISA analysis of amyloid - beta can be recovered by a novel sample pre - treatment method, MethodsX 2 (2015) pp. 112 - 123 [9]Sun et al., Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS / TLS, PLoS Biology, April 2011 | 9 Vol. | 4 Issue | e1000614

[10] Couthuis et al., Evaluating the role of the FUS / TLS - related gene EWSR1 in amyotrophic lateral sclerosis, Human Molecular Genetics, 2012, 21 Vol., 13 Issue pp. 2899 - 2911

[11] Ryan et al., Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization, (2013), PeerJ 1:e73; DOI 10.7717 / peerj.73

[12] Dormann et al., Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin, (2009), Journal of Neurochemistry, vol. 110, pp. 1082-1094.

[13] Couthuis et al., A yeast functional screen predicts new candidate ALS disease genes, PNAS | December 27, 2011 | Volume 108 | Issue 52 | Pages 20881-20890

Claims

1. 1. An in vitro method for detecting the beta-sheet aggregate form of a protein that forms beta-sheet aggregates (PAFβ) in a sample, comprising the steps of: a) In a first container: a1) introducing a sample likely to contain PAFβ; a2) adjusting the pH to a range of 9.7-13.2 using NaOH to disaggregate all or part of the β-sheet aggregate-forming protein (PNAFβ) to obtain a β-sheet non-aggregated form of the PAFβ; a3) adjusting the pH to a pH in the range of 6 to 9 using HCl; b) measuring the PNAFβ content in the first container using the RET method; c) In a second container: c1) adding the same sample as in step a1); c2) adjusting the pH to a pH in the range of 6 to 9 using a NaOH / HCl mixture; d) measuring the PNAFβ content in the second container using the same method as in step b); e) comparing the contents measured in steps b) and d), wherein a decrease in the content measured in step d) compared to the content measured in step b) indicates that the sample contains PAFβ. Including, The protein that forms β-sheet aggregates is α-synuclein or TDP-43. method.

2. The method of claim 1, wherein the sample is derived from an individual having or suspected of having a disease associated with PAFβ.

3. The method of claim 1 or 2, wherein the sample is derived from cells or tissues cultured in vitro.

4. The method of any one of claims 1 to 3, wherein the sample is selected from a blood sample, a plasma sample, a serum sample, a cerebrospinal fluid sample, a cell lysate, a cell homogenate, a tissue lysate or a tissue homogenate.

5. A method according to any one of claims 1 to 4, wherein the sample is a brain homogenate.

6. 4. The method of claim 1 or 3, wherein the sample is selected from a cell lysate, a cell homogenate, a tissue lysate, a tissue homogenate, a cell culture supernatant, a tissue culture supernatant, a cell subfraction or a protein (native or recombinant).

7. The immunological method carried out in steps b) and d) comprises (i) a ligand capable of specifically binding to PNAFβ, the ligand being labeled with a tracer; or (ii) a pair of ligands capable of specifically binding to PNAFβ, wherein at least one ligand of the pair of ligands is labeled with a tracer; The method according to any one of claims 1 to 6, wherein

8. - the ligand (i) is selected from an antibody, an antibody fragment, a peptide or an aptamer, or The method according to claim 7, wherein the pair of ligands (ii) is selected from a pair of antibodies, a pair of antibody fragments, a pair of peptides or a pair of aptamers.

9. - The method of claim 8, wherein the ligand pair (ii) is an antibody pair.

10. Steps b) and d) are carried out by the RET method, (b1) placing in a container a first PNAFβ ligand labeled with a first member of a RET partner pair and a second PNAFβ ligand labeled with a second member of a RET partner pair, wherein the pair of ligands are capable of specifically binding to PNAFβ; (b2) measuring the emitted RET signal in the container; (d1) placing in a container a first PNAFβ ligand labeled with a first member of a pair of RET partners and a second PNAFβ ligand labeled with a second member of a pair of RET partners, wherein the pair of ligands are capable of specifically binding to PNAFβ; and (d2) measuring the emitted RET signal in the container The method according to any one of claims 1 to 9, comprising:

11. 1. An in vitro method for monitoring the therapeutic efficacy of a treatment for a disease associated with PAFβ in a patient, comprising the steps of: A) carrying out the method according to any one of claims 1 to 9 on a first sample of said patient, wherein step e) consists in determining the ratio between the content measured in step b) and the content measured in step d), B) carrying out the same method as in step A) on a second sample from said patient to determine the ratio between the content measured in step b) and the content measured in step d); C) Comparing the ratios determined in steps A) and B), and observing therapeutic efficacy when the ratio determined in step B) is lower than the ratio determined in step A). Including, the first sample was obtained from the patient at an earlier time point than the second sample; method.

12. An in vitro method for determining the pharmacological efficacy of a drug molecule or drug candidate against a disease associated with PAFβ in a test sample, comprising the steps of: A) carrying out the method according to any one of claims 1 to 10 on a first sample of said test sample, wherein step e) consists in determining the ratio between the content measured in step b) and the content measured in step d), B) performing the same method as in step A) on a second sample of said test sample to determine the ratio between the content measured in step b) and the content measured in step d); C) comparing the ratios determined in steps A) and B), and observing pharmacological efficacy if the ratio determined in step B) is lower than the ratio determined in step A). Including, the first sample was obtained from the patient at an earlier time point than the second sample; method.

Images